search
Back to results

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Primary Purpose

Retinitis Pigmentosa

Status
Recruiting
Phase
Phase 2
Locations
Indonesia
Study Type
Interventional
Intervention
1.5 x 10^6 UC-MSC + CM
5 x 10^6 UC-MSC + CM
Sponsored by
PT. Prodia Stem Cell Indonesia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Retinitis Pigmentosa focused on measuring Allogeneic Mesenchymal Stem Cell, Umbilical Cord Mesenchymal Stem Cell, Conditioned Medium, Allogeneic Umbilical Cord Mesenchymal Stem Cell

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Visus more than 20/100 Have more than 0.68 uV on conical receptor cell amplitude checked by ERG Visual field equivalent diameter more than 10o Willing to sign informed consent as research subjects Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations, and fill out a quality of life questionnaire Exclusion Criteria: Pregnant or nursing women Positive result of HIV test Have a history of eye tumors Under immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma Do not come to control according to the schedule determined by the researcher (loss to follow up)

Sites / Locations

  • RSUP Dr. SardjitoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

EYESTEM 001-X

EYESTEM 001-XF

Arm Description

1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.

1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.

Outcomes

Primary Outcome Measures

Incident of Adverse Events
assessment of infection, inflammation, eye pressure and patients complaints
Incident of Adverse Events
assessment of infection, inflammation, eye pressure and patients complaints
Frequency of Adverse Events
assessment of infection, inflammation, eye pressure and patients complaints
Frequency of Adverse Events
assessment of infection, inflammation, eye pressure and patients complaints
Visual Acuity Test
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Visual Acuity Test
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Visual Acuity Test
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Visual Acuity Test
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Visual Field Test
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Visual Field Test
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Visual Field Test
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Visual Field Test
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Funduscopy
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Funduscopy
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Funduscopy
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Funduscopy
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Electrorectinography
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Electrorectinography
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Electrorectinography
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Electrorectinography
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Optical Coherence Tomography (OCT)
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Optical Coherence Tomography (OCT)
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Optical Coherence Tomography (OCT)
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Optical Coherence Tomography (OCT)
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.

Secondary Outcome Measures

Patients Quality of Life
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Patients Quality of Life
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Patients Quality of Life
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Patients Quality of Life
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Pain evaluation
Evaluation on level of pain felt by patients
Eye bump
Evaluation on appearance of eye bump

Full Information

First Posted
March 14, 2023
Last Updated
August 2, 2023
Sponsor
PT. Prodia Stem Cell Indonesia
search

1. Study Identification

Unique Protocol Identification Number
NCT05909488
Brief Title
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
Official Title
Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
December 1, 2025 (Anticipated)
Study Completion Date
December 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PT. Prodia Stem Cell Indonesia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.
Detailed Description
The eyes we will give the transplant should be given an aseptic and antiseptic technique to prevent contamination from the inside and outside. Sterile cover attached to other parts of the face except for the eyes. 1.8 ml Umbilical Cord-derived Mesenchymal Stem Cell (UC-MSC) preparations are suspended in Conditioned Medium (CM) until it reaches a 2 ml volume of cell suspension. Two dosages will be prepared, 1.5 million and 5 million of UC-MSC. Stem cell suspension will be injected by peribulbar, and patients will be given a quinolone antibiotic if the injection is done. On day 1st and day 7th after therapy, patients will be observed the presence of infection, inflammation, and increased eye pressure. On day 7th, day 30th, and day 90th after therapy, patients will do a visual field test, visual acuity test, electroretinography, funduscopy, and Optical Coherence Tomography examination. The observations will be written in the table and analyzed by a statistic.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinitis Pigmentosa
Keywords
Allogeneic Mesenchymal Stem Cell, Umbilical Cord Mesenchymal Stem Cell, Conditioned Medium, Allogeneic Umbilical Cord Mesenchymal Stem Cell

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
EYESTEM 001-X
Arm Type
Experimental
Arm Description
1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.
Arm Title
EYESTEM 001-XF
Arm Type
Experimental
Arm Description
1.8 ml cell preparations are suspended in Conditioned Media (CM) until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected into the peribulbar.
Intervention Type
Biological
Intervention Name(s)
1.5 x 10^6 UC-MSC + CM
Intervention Description
1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
Intervention Type
Biological
Intervention Name(s)
5 x 10^6 UC-MSC + CM
Intervention Description
5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
Primary Outcome Measure Information:
Title
Incident of Adverse Events
Description
assessment of infection, inflammation, eye pressure and patients complaints
Time Frame
1 day after injection
Title
Incident of Adverse Events
Description
assessment of infection, inflammation, eye pressure and patients complaints
Time Frame
1 week after injection
Title
Frequency of Adverse Events
Description
assessment of infection, inflammation, eye pressure and patients complaints
Time Frame
1 day after injection
Title
Frequency of Adverse Events
Description
assessment of infection, inflammation, eye pressure and patients complaints
Time Frame
1 week after injection
Title
Visual Acuity Test
Description
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Time Frame
1 week after injection
Title
Visual Acuity Test
Description
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Time Frame
1 month after injection
Title
Visual Acuity Test
Description
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Time Frame
3 months after injection
Title
Visual Acuity Test
Description
a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.
Time Frame
6 months after injection
Title
Visual Field Test
Description
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Time Frame
1 week after injection
Title
Visual Field Test
Description
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Time Frame
1 month after injection
Title
Visual Field Test
Description
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Time Frame
3 months after injection
Title
Visual Field Test
Description
a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humphrey's perimetry.
Time Frame
6 months after injection
Title
Funduscopy
Description
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Time Frame
1 week after injection
Title
Funduscopy
Description
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Time Frame
1 month after injection
Title
Funduscopy
Description
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Time Frame
3 months after injection
Title
Funduscopy
Description
an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.
Time Frame
6 months after injection
Title
Electrorectinography
Description
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Time Frame
1 week after injection
Title
Electrorectinography
Description
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Time Frame
1 month after injection
Title
Electrorectinography
Description
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Time Frame
3 months after injection
Title
Electrorectinography
Description
an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.
Time Frame
6 months after injection
Title
Optical Coherence Tomography (OCT)
Description
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Time Frame
1 week after injection
Title
Optical Coherence Tomography (OCT)
Description
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Time Frame
1 month after injection
Title
Optical Coherence Tomography (OCT)
Description
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Time Frame
3 months after injection
Title
Optical Coherence Tomography (OCT)
Description
is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities.
Time Frame
6 months after injection
Secondary Outcome Measure Information:
Title
Patients Quality of Life
Description
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Time Frame
1 week after injection
Title
Patients Quality of Life
Description
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Time Frame
1 month after injection
Title
Patients Quality of Life
Description
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Time Frame
3 months after injection
Title
Patients Quality of Life
Description
Patient's quality of life using National Eye Institute-Visual Functional Questioner 25
Time Frame
6 months after injection
Title
Pain evaluation
Description
Evaluation on level of pain felt by patients
Time Frame
6 months after injection
Title
Eye bump
Description
Evaluation on appearance of eye bump
Time Frame
6 months after injection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Visus more than 20/100 Have more than 0.68 uV on conical receptor cell amplitude checked by ERG Visual field equivalent diameter more than 10o Willing to sign informed consent as research subjects Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations, and fill out a quality of life questionnaire Exclusion Criteria: Pregnant or nursing women Positive result of HIV test Have a history of eye tumors Under immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma Do not come to control according to the schedule determined by the researcher (loss to follow up)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
dr. Muhammad B Sasongko, Sp.M, M.Epid, PhD
Phone
+62811293476
Email
mb.sasongko@ugm.ac.id
First Name & Middle Initial & Last Name or Official Title & Degree
Dr. Cynthia R Sartika, M.Si
Email
cynthia.sartika@prostem.co.id
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
dr. Muhammad B Sasongko, Sp.M, M.Epid, PhD
Organizational Affiliation
Gadjah Mada University, Faculty of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
dr. Cosmos O Mangunsong, Sp.M
Organizational Affiliation
Jakarta Eye Center
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
dr. Rifa Widyaningrum, M.Sc, PhD
Organizational Affiliation
Sardjito Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Rima Haifa, S.Si
Organizational Affiliation
Prodia StemCell Indonesia
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Marsya N Kirana, S.T., M.Sc
Organizational Affiliation
Prodia StemCell Indonesia
Official's Role
Study Chair
Facility Information:
Facility Name
RSUP Dr. Sardjito
City
Yogyakarta
State/Province
DI Yogyakarta
ZIP/Postal Code
55284
Country
Indonesia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rifa Widyaningrum, PhD
Phone
082134546400
First Name & Middle Initial & Last Name & Degree
Bayu Sasongko, PhD
First Name & Middle Initial & Last Name & Degree
Cosmos Mangunsong, Dr

12. IPD Sharing Statement

Learn more about this trial

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

We'll reach out to this number within 24 hrs